Story perspectives

Poll: 70% Favor In-Person Mifepristone Prescriptions Amid Safety Concerns

11/4/2025

36 8

Summary

Story summary

A poll by McLaughlin & Associates shows 70% want an in-person visit to prescribe mifepristone.
The survey finds 87% want the U.S. Food and Drug Administration (FDA) to report real-world effects accurately, and 81% oppose online access to abortion drugs without consent.
Skepticism about mifepristone's safety persists, with 60% believing it is more dangerous than advertised.
The FDA recently approved a generic version of mifepristone, raising doubts about safety.

1 of 1

Story summary

A poll by McLaughlin & Associates shows 70% want an in-person visit to prescribe mifepristone.
The survey finds 87% want the U.S. Food and Drug Administration (FDA) to report real-world effects accurately, and 81% oppose online access to abortion drugs without consent.
Skepticism about mifepristone's safety persists, with 60% believing it is more dangerous than advertised.
The FDA recently approved a generic version of mifepristone, raising doubts about safety.